Table 1 Main characteristics of the selected researches
Study cohort | Study design | Year (study duration) | Study region | No. (LPS/LPT) | Age (years) | Outcome | Follow up (months) | BMI (kg/m2) | Tumor size (cm)(LPS/LPT) | Method of tumor extraction | No. of tumor spillage (LPS/LPT) | No. of lymph nodes removed (LPS/LPT) | No. of upstaging (LPS/LPT) | No. of adjuvant therapy (LPS/LPT) | No. of recurrence (LPS/LPT) | No. of port-site metastasis (LPS/LPT) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Lu, Q. | retrospective study | 2016 | China | 42/50 | LPS:54 (14–69) | OS | 82 (16–152) | LPS:23.5 ± 4.0 | NR | capsule bag | NR | 20/22 | 9/10 | 12/15 | 5/6 | 0 |
(2002–2014) | LPT:58 (25–76) | LPT:24.8 ± 3.2 | ||||||||||||||
Minig, L. | retrospective comparative observational study | 2016 | Spain | 50/58 | LPS:52 (44.8–62.3) | OS/PFS | LPS:25.9 (11.2–38.5) | LPS:23.7 (21.8–27.2) | 6.75 / 10.0 | endo-bag | NR | 15/13.5 | 12/8 | 32/34 | 1/7 | 0 |
(2006–2014) | LPT:52 (44.8–65) | LPT:34.3 (28.4–47.8) | LPT:24.6 (21.8–28.5) | |||||||||||||
Gallotta, V. | retrospective case-control study | 2016 | Italy | 60/120 | LPS:48 (24–73) | OS/PFS | 38 (24–48) | NR | NR | NR | NR | 16/ 18 | NR | 70%, similar between LPS/LPT | 5/16 | 0 |
(LPS:2007–2013;LPT:2000–2011) | LPT:55 (22–81) | |||||||||||||||
Ditto, A. | retrospective study | 2017 | Italy | 50/50 | LPS:46.0 ± 13.4 | OS/PFS | LPS:49.5 ± 64 | LPS:25.1 ± 3.4 | NR | NR | NR | 31/36 | 10/13 | 31/28 | NR | 0 |
(2005–2015) | LPT:42.8 ± 11.2 | LPT:52.6 ± 31.7 | LPT:25.8 ± 5.1 | |||||||||||||
Xiong, W. | retrospective study | 2017 | China | 71/31 | LPS:47 ± 10 | OS | 50.5 | LPS:23 ± 4 | 8/14 | capsule bag | NR | 18.1/15.5 | 7/2 | 67/59 | 11/4 | 0 |
(2007–2014) | LPT:49 ± 10 | LPT:22 ± 3 | ||||||||||||||
Merlier, M. | retrospective study | 2000–2018 | France | 37/107 | LPS:56.3 ± 16.8 | OS/PFS | LPS:24 (11–50) | LPS:23.8 ± 5.0 | NR | NR | NR | 28/67 | NR | 34/96 | 2/31 | 0 |
LPT:56.2 ± 14.7 | LPT:42 (22–66) | LPT: 25.4 ± 5.0 |